[Concurrent weekly nedaplatin-based radiotherapy for high risk, recurrent and advanced cervical cancer].
Advanced cervical cancer has been predominantly treated with a combination of external beam and brachytherapy in Japan. Recent studies suggest concurrent use of cisplatin and radiation treatment has superior disease control to radiation only treatment. We have conducted a phase I pilot study of concurrent use of weekly nedaplatin (30 mg/m2) and sequential external beam and brachytherapy in advanced stage or recurrent uterine cervical cancer patients (n = 6). All patients completed the treatment without serious complications. Five patients had complete responses and one a partial response. The average AUC of nedaplatin after one administration was 5.0 micrograms/ml.hr. The therapeutic index was 2. We concluded that concurrent use of weekly nedaplatin and radiation is well tolerated by Japanese women, and may well be an excellent therapeutic modality for selected cases of advanced or recurrent cervical cancer.
Idei
Tomoko
T
Dept. of Obstetrics and Gynecology, Nihon University School of Medicine.
Sakamoto
Hideki
H
Nakajima
Yoshiyuki
Y
Hiraiwa
Yukiko
Y
Takami
Noriko
N
Chishima
Fumihisa
F
Ohtani
Kaori
K
Nagaishi
Masaji
M
Yamamoto
Tatsuo
T
Kawamori
Jiro
J
Himi
Kazuhisa
K
Tanaka
Yoshiaki
Y
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D010865:Pilot Projects; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin